Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Keith Bloom

Urology Irving, TX Medical Doctor

NPI 1831177948 CMS profile 264654

7701 Las Colinas Rdg Ste 460, Irving, TX 75063

Open in the dashboard

General payments

$7,762

325 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Keith Bloom of Irving, TX is reported in the CMS Open Payments database as having received $7,762 across 325 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 75th percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,134 40
2024 General $1,364 53
2023 General $686 28
2022 General $1,508 64
2021 General $1,248 66
2020 General $741 40
2019 General $1,081 34

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Keith Bloom
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Keith Bloom were reported at $1,134. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Keith Bloom Urology median Middle half National median
2019 $1,081 $480 $147–$1,201 $163
2020 $741 $246 $87–$645 $114
2021 $1,248 $358 $111–$1,000 $132
2022 $1,508 $476 $143–$1,263 $149
2023 $686 $560 $168–$1,461 $160
2024 $1,364 $563 $170–$1,464 $164
2025 $1,134 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Astellas Pharma US Inc $1,220 72 payments
  2. Boston Scientific Corporation $925 24 payments
  3. Janssen Biotech, Inc. $650 22 payments
  4. AbbVie, Inc. $506 25 payments
  5. Sumitomo Pharma America, Inc. $488 25 payments
  6. Blue Earth Diagnostics Limited $283 12 payments
  7. Dendreon Pharmaceuticals LLC $274 13 payments
  8. Pfizer Inc. $268 13 payments
  9. Olympus America Inc. $221 8 payments
  10. Ferring Pharmaceuticals Inc. $218 6 payments
  11. Other $2,708 105 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,510 320 payments
  2. Education $138 4 payments
  3. Grant $114 1 payment
Products named General payments · program years 2019–2025
  1. XTANDI $829 49 payments
  2. MYRBETRIQ $684 42 payments
  3. ERLEADA $589 21 payments
  4. ORGOVYX $432 20 payments
  5. LUPRON DEPOT $422 20 payments
  6. PROVENGE $274 13 payments
  7. iTIND System $221 8 payments
  8. GEMTESA $217 12 payments
  9. UROLIFT $213 5 payments
  10. Nubeqa $186 8 payments
  11. Other $4,039 150 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 16 drugs

Part D claims

1,052

Median for Urology: 1,053

Drug cost

$94,054

Median for Urology: $101,464

Branded share of claims

27%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 94 $57,680
Gemtesa Vibegron Brand 33 $24,746
Tamsulosin Hcl Generic 414 $3,513
Finasteride Generic 220 $2,909
Oxybutynin Chloride Er Oxybutynin Chloride Brand 81 $2,094
Methenamine Hippurate Generic 18 $929
Cephalexin Generic 39 $429
Dutasteride Generic 14 $425
Alfuzosin Hcl Er Alfuzosin Hcl Brand 13 $338
Nitrofurantoin Nitrofurantoin Macrocrystal Brand 13 $332

The 10 drugs with the highest cost, of 16 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 102 billing codes

Paid by Medicare

$205,349

Of which drugs: $10,177

Medicare patients

720

Average age 75

Services billed

4,794

136 women, 584 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 43%
Diabetes 36%
Chronic kidney disease 35%
Ischemic heart disease 34%
Cancer 31%
Atrial fibrillation 22%
Heart failure 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, ceftriaxone sodium, per 250 mg J0696 Office 29 116 $42

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ERLEADA
  • Janssen Biotech, Inc. $133
$133 — —
ORGOVYX
  • Sumitomo Pharma America, Inc. $125
  • PFIZER INC. $7
$132 — —
GEMTESA
  • Sumitomo Pharma America, Inc. $96
$96 33 —
PROVENGE
  • Dendreon Pharmaceuticals LLC $92
$92 — —
AKEEGA
  • Janssen Biotech, Inc. $58
$58 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

325 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record